Corvidia: Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab

Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD).The post Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab appeared first on Pharmaceutical Business review.